Abiopharma

🔍 Lloyd Jason Michael (Executive)

Company: Velo3D, Inc. (VELO)

Report Date: 2026-06-12

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-12 | Code: H | shares_owned_after: 11,187.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-12 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 7,000.00 | Footnotes: F1
• Acquired 7,843 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-12 | Code: A | equity_swap_involved: false | shares_owned_after: 11,031.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: The reported securities are held in an individual retirement account ("IRA") for the benefit of the reporting person.
• F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Velo3D, Inc. (the "Company"), granted under the Company's 2021 Equity Incentive Plan. The Compensation Committee (the "Committee") of the Board of Directors of the Company, in its sole discretion, may settle earned RSUs in cash, shares of common stock of the Company, or a combination of both.
• F3: The RSUs shall vest as to 25% of the total grant quarterly, commencing September 12, 2026, with the remainder of grant vesting on each subsequent quarter, December 12, 2026, March 12, 2027 and June 12, 2027, subject to the Reporting Person's continued service to the Issuer on each vesting date.